Palbociclib/Proton Pump Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

How this interaction occurs is not fully understood but may be related to the effects of proton pump inhibitors on your gut bacteria or stomach acid. Palbociclib needs some stomach acid to be absorbed into your body. Proton pump inhibitors decrease the amount of acid in your stomach.

What might happen:

The amount of palbociclib in your blood may decrease. Your therapy may not work as well.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. You may need to change your medicine to avoid an interaction. If you have any questions about how or when to take your medicine, ask your pharmacist.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Ibrance (palbociclib) US prescribing information. Pfizer Labs September, 2023.
  • 2.Chang YC, Song J, Chang Y, Huang CH, Sudan A, Chen PC, Chi KY. The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+ /HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers (Basel) 2023 Oct 25;15(21):.
  • 3.Lee JE, Kwon SH, Kwon S, Jung HI, Nam JH, Lee EK. Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer. JAMA Netw Open 2023 Jul 3;6(7):e2324852.
  • 4.Di Cosimo S, Perez-Garcia JM, Ezquerra MB, Dalenc F, Gil MG, Borrego MR, Gavila J, Sampayo-Cordero M, Aguirre E, Schmid P, Marme F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D. Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+ /HER2- ABC): Exploratory Analysis of the PARSIFAL Trial abstract. Cancer Res 2023 March;83(5 Suppl):PD13-10.
  • 5.Caglayan D, Kocak MZ, Geredeli C, Tatli AM, Goksu SS, Eryilmaz MK, Araz M, Artac M. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. Eur J Clin Pharmacol 2023 Feb;79(2):243-248.
  • 6.Eser K, Onder AH, Sezer E, Cil T, Inal A, Ozturk B, Ercolak V, Duman BB, Celik H, Koseci T, Kesen O. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer 2022 May 7;22(1):516.
  • 7.Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 2021 Oct;6(5):100231.
  • 8.Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, . Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer. Oncologist 2024 Feb 10.
  • 9.Schieber T, Steele S, Collins S, Berger M, Fleming M, McLaughlin E, Sudheendra P, Vargo C. Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer. Clin Breast Cancer 2023 Aug;23(6):658-663.
  • 10.Odabas H, Dogan A, Ozcelik M, Yildirim S, Ozkerim U, Turan N, Yildirim ME, Gumus M. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. Medicina (Kaunas) 2023 Mar 12;59(3):.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.